Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis.

Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell'Unto C, Lai Q, Cabibbo G, Sacco R, Villa E, Trevisani F.

Expert Opin Drug Saf. 2019 Jul;18(7):603-610. doi: 10.1080/14740338.2019.1617272. Epub 2019 May 20.

PMID:
31067134
2.

Retraction: Carulli, L. et al. The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). Metabolites 2019, 9(2), 25.

Carulli L, Zanca G, Schepis F, Villa E; Metabolites Editorial Office.

Metabolites. 2019 Apr 11;9(4). pii: E70. doi: 10.3390/metabo9040070.

3.

Obese zebrafish: A small fish for a major human health condition.

Faillaci F, Milosa F, Critelli RM, Turola E, Schepis F, Villa E.

Animal Model Exp Med. 2018 Nov 21;1(4):255-265. doi: 10.1002/ame2.12042. eCollection 2018 Dec. Review.

4.

Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study.

Gitto S, Vizzutti F, Schepis F, Turco L, Aspite S, Vitale G, Arena U, Villa E, Laffi G, Debernardi-Venon W, Fanelli F, Andreone P, Marra F; DAA-TIPS group.

Dig Liver Dis. 2019 Jun;51(6):870-874. doi: 10.1016/j.dld.2018.11.015. Epub 2019 Feb 7.

PMID:
30824409
5.

Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma.

Todesca P, Marzi L, Critelli RM, Cuffari B, Caporali C, Turco L, Pinelli G, Schepis F, Carulli L, de Maria N, Casari F, Scaglioni R, Villa E.

Hepatology. 2019 Feb 25. doi: 10.1002/hep.30588. [Epub ahead of print]

PMID:
30802985
6.

Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times.

Gitto S, Marra F, De Maria N, Bihl F, Villa E, Andreone P, Burra P.

Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):173-178. doi: 10.1080/17474124.2019.1551132. Epub 2018 Nov 30.

PMID:
30791778
7.

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD).

Carulli L, Zanca G, Schepis F, Villa E.

Metabolites. 2019 Feb 1;9(2). pii: E25. doi: 10.3390/metabo9020025. Review. Retraction in: Metabolites. 2019 Apr 11;9(4):.

8.

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.

Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Fagiuoli S, Belli L, Verucchi G, Puoti M, Craxì A.

Sci Rep. 2019 Jan 24;9(1):585. doi: 10.1038/s41598-018-36734-0.

9.

SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer.

Zubiete-Franco I, García-Rodríguez JL, Lopitz-Otsoa F, Serrano-Macia M, Simon J, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gutiérrez-de-Juan V, López de Davalillo S, Carlevaris O, Beguiristain Gómez A, Villa E, Calvisi D, Martín C, Berra E, Aspichueta P, Beraza N, Varela-Rey M, Ávila M, Rodríguez MS, Mato JM, Díaz-Moreno I, Díaz-Quintana A, Delgado TC, Martínez-Chantar ML.

EBioMedicine. 2019 Feb;40:406-421. doi: 10.1016/j.ebiom.2018.12.031. Epub 2018 Dec 26.

10.

Reply to: "It takes two "eyes" to see in depth".

Turco L, Garcia-Tsao G, Rossi R, Villa E, Schepis F.

J Hepatol. 2019 Apr;70(4):791-793. doi: 10.1016/j.jhep.2018.12.002. Epub 2018 Dec 24. No abstract available.

PMID:
30591265
11.

The Role of Anticoagulation in Treating Portal Hypertension.

Turco L, Schepis F, Villa E.

Curr Hepatol Rep. 2018;17(3):200-208. doi: 10.1007/s11901-018-0406-x. Epub 2018 Jun 18. Review. Erratum in: Curr Hepatol Rep. 2018;17(4):511.

12.

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir.

Viganò M, Loglio A, Labanca S, Zaltron S, Castelli F, Andreone P, Messina V, Ganga R, Coppola N, Marrone A, Russello M, Marzano A, Tucci A, Taliani G, Fasano M, Fagiuoli S, Villa E, Bronte F, Santantonio T, Brancaccio G, Occhipinti V, Facchetti F, Grossi G, Rumi M, Lampertico P.

Liver Int. 2019 Mar;39(3):484-493. doi: 10.1111/liv.14017. Epub 2019 Jan 7.

PMID:
30525275
13.

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.

Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M; collaborators.

Dig Liver Dis. 2019 Feb;51(2):310-317. doi: 10.1016/j.dld.2018.10.014. Epub 2018 Oct 31.

PMID:
30473220
14.

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials.

Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ.

Open Forum Infect Dis. 2018 Sep 27;5(11):ofy248. doi: 10.1093/ofid/ofy248. eCollection 2018 Nov.

15.

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.

Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL.

J Viral Hepat. 2019 Mar;26(3):337-349. doi: 10.1111/jvh.13038. Epub 2018 Dec 11.

PMID:
30421537
16.

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis.

Fernández-Ramos D, Fernández-Tussy P, Lopitz-Otsoa F, Gutiérrez-de-Juan V, Navasa N, Barbier-Torres L, Zubiete-Franco I, Simón J, Fernández AF, Arbelaiz A, Aransay AM, Lavín JL, Beraza N, Perugorria MJ, Banales JM, Villa E, Fraga MF, Anguita J, Avila MA, Berasain C, Iruzibieta P, Crespo J, Lu SC, Varela-Rey M, Mato JM, Delgado TC, Martínez-Chantar ML.

Cell Death Dis. 2018 Sep 20;9(10):958. doi: 10.1038/s41419-018-1014-y.

17.

Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis.

Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, Morisco F; Special Interest Group on Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver.

Dig Liver Dis. 2018 Nov;50(11):1105-1114. doi: 10.1016/j.dld.2018.08.001. Epub 2018 Aug 11. Review.

PMID:
30170908
18.

Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference.

Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F; faculty of the 7th International Coagulation in Liver Disease.

Thromb Haemost. 2018 Aug;118(8):1491-1506. doi: 10.1055/s-0038-1666861. Epub 2018 Jul 30. No abstract available.

19.

Prevention and Management of Bleeding Risk Related to Invasive Procedures in Cirrhosis.

Schepis F, Turco L, Bianchini M, Villa E.

Semin Liver Dis. 2018 Aug;38(3):215-229. doi: 10.1055/s-0038-1660523. Epub 2018 Jul 24. Review.

PMID:
30041274
20.

Reply to: "Relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis".

Turco L, Garcia-Tsao G, Rossi R, Villa E, Schepis F.

J Hepatol. 2018 Sep;69(3):748-749. doi: 10.1016/j.jhep.2018.05.023. Epub 2018 Jun 2. No abstract available.

PMID:
29870763

Supplemental Content

Loading ...
Support Center